ESH-EHA SCIENTIFIC WORKSHOP Innovative Therapies for Red

advertisement

ESH-EHA SCIENTIFIC WORKSHOP

Innovative Therapies for Red Cell and Iron related Disorders

April 15-18, 2010

Cascais, Portugal

Organizing Committee:

Clara Camaschella, Eliane Gluckman, Philippe Leboulch,

Carole Beaumont, Mohandas Narla, Yves Beuzard

Invited speakers:

Christopher Baum (Hannover), Carole Beaumont (Paris), Françoise Bernaudin (Creteil), Yves Beuzard (Fontenay),

Clara Camaschella (Milano), Francois-Loic Cosset (Lyon), Ioav Cabantchick (Jerusalem), George Daley (Boston),

Ivana de Domenico (Salt Lake City), Frederic Galacteros (Creteil), Eliane Gluckman (Paris), Frank Grosveld (Rotterdam),

Keith Humphries (Vancouver), Philippe Leboulch (Fontenay/Boston), Franco Locatelli (Pavia),

Narla Mohandas (New-York), Elizabeta Nemeth (Los Angeles), Stuart Orkin (Boston), Marie-Paul Roth (Toulouse),

Miguel Soares (Lisbon), Pierre-Louis Tharaux (Paris), Swe Lee Thein (London)

Objectives:

1) Stimulation of research on innovative therapies of red cell and iron disorders, from targets to bedside, including preclinical and clinical trials.

2) Presentation of original results (invited speakers, selected oral presentations and posters).

2) Cooperation between clinicians and scientists, in order to define new targets, to develop and evaluate experimental therapies.

ESH-EHA JOINT ACTIVITY

SPONSORSIP OPPORTUNITIES

WHO ARE WE?

The European School of Haematology (ESH) and the European Hematology Association (EHA) have collaborated together on major educational projects for many years. This relationship was formalized in

February 2008 through the establishment of a Joint Executive Committee (JEC) represented by E. Gluckman

(ESH), W. Fibbe (EHA), B. Löwenberg (ESH) and R. Foà (EHA). The JEC’s mandate is to optimize current joint-educational activities and to develop new initiatives to anticipate and respond to the rapidly evolving educational needs of hematologists.

WHAT DO WE DO?

The joint ESH and EHA committee organizes in-depth scientific workshops and tutorials on specific topics of importance to basic, translational and clinical research scientists working in the field of haematology. Topics are selected to complement those addressed at the annual EHA congress and those treated during other

ESH activities. Also hematologists who are interested in organizing a scientific workshop or tutorial are invited to send in an application through the websites of EHA or ESH.

ESH-EHA Scientific Workshops are residential meetings open to 150-200 scientists working in different settings. Each Scientific Workshop focuses on one specific topic. They are 2,5-day full-immersion meetings with state-of-the-art programs and presentation of late-breaking data. The program also provides many opportunities for direct interaction between the registered delegates and the members of the faculty.

The topics of past workshops include Mesenchymal Stem Cells, Biomarkers and Prognosis in Malignant

Lymphomas, Molecular Prognostic Factor in AML and Immunogenicity of Coagulation Factors.

ESH-EHA Hematology Tutorials are 3-day meetings that aim to provide laboratory and clinical hematologists with an integrated diagnostic and clinical work-up of hematological disorders. Tutorial programs include plenary lectures, interactive clinical case study sessions and opportunities for self-assessment. They use voting box technology.

There are three types of tutorials. The clinical cases and self-assessment quizzes developed for the tutorials are subsequently uploaded onto the EHATol platform.

TYPE I Tutorials present newly developed clinical cases, lectures and multiple choice self-assessment tests.

TYPE II Tutorials are designed to bring the educational materials of TYPE I tutorials to a wider audience; they can easily travel throughout Europe and beyond. They present new lectures and clinical cases and selfassessment tests initially developed for TYPE I Tutorials.

The EHATOL Platform is where the clinical cases and self assessment test presented at ESH-EHA

Hematology Tutorials are available following the Type I tutorials. The EHATol platform is on both the ESH and EHA websites: www.esh.org www.ehaweb.org

HOW CAN COMPANIES SPONSOR ESH EHA JOINT ACITIVITEIS?

Partnerships options include offering unrestricted educational grants for a Scientific Workshop, Type I or

Type II Hematology Tutorial;

WHAT ARE THE ADVANTAGES OF SPONSORSHIP ?

Your unrestricted educational grant and your company logo will be acknowledged before, onsite and after the event sponsored. Your logo will be included on all promotional documents, on-site on posters and conference materials, and after the conference on the ESH and EHA websites and in newsletters.

WHAT ARE THE TYPES OF SPONSORSHIP AVAILABLE ?

There are four levels of sponsorship.

1. ESH – EHA Workshop/Tutorial-Premium-Level partner: 20 000€

Before the Workshop or Tutorial Acknowledgements:

- Acknowledgement as a workshop premium level partner on all printed and electronic promotional documents

- Acknowledgement as a workshop premium level partner on the EHA and ESH websites

- Establishment of a hyperlink with the ESH and EHA website.

On-site the Workshop or Tutorial – Acknowledgements:

- Prime exhibit space.

- Acknowledgement within the teaching materials and on posters

- Acknowledgement on the invitation to the conference welcome get-together

- 2 complimentary full Workshop/Tutorial registrations

- Discounted registration rate for all groups of delegates registered by the corporate partner’s national branches worldwide

- Advertisement on back cover of educational materials .

After the Workshop/Tutorial.

- Acknowledgement of your sponsorship and company logo in Newsletter and on the ESH and

EHA websites.

2. ESH – EHA Workshop/Tutorial-Major-Level P artner: 10 000€

Before the Workshop or Tutorial – Acknowledgement:

- Acknowledgement as a workshop major level partner on all printed and electronic promotional documents

- Acknowledgement as a workshop major level partner on the EHA and ESH websites.

On-site the Workshop or Tutorial – Acknowledgements:

- Prime exhibit space

- acknowledgement within the teaching materials and on posters

- Discounted registration rate of 10% for all groups of delegates registered by the corporate partner’s national branches worldwide.

After the Workshop/Tutorial.

- Acknowledgement of your sponsorship and company logo in Newsletter and on the ESH and

EHA websites.

3. ESH – EHA Workshop/Tutorial-Conference Partner: 5 000€

Acknowledgement as a workshop conference partner on all printed and electronic promotional documents

Booth space

4. ESH – EHA Workshop/Tutorial-Exhibitor : 1 500€

Booth Space

All Workshop/Tutorial Partners will be offered the possibility to book a hotel room at the same rate as participants of the workshop/tutorial and they will be awarded 5 priority points for the EHA Priority Points

System, with a maximum of 10 points per year

ARE THERE OTHER SPONSORSHIP OPTIONS?

Yes, your company may also sponsor.

Distribution of flyers

Sponsor of onsite meals

Sponsor of welcome cocktail

Sponsor coffee/tea breaks (4 times)

A4 advertisement in Education book

HOW CAN I EXPRESS MY INTEREST IN SPONSORING

AN ESH EHA WORKSHOP OR TUTORIAL?

Should you be interested in sponsoring a tutorial or a workshop, please do not hesitate to contact either the

ESH or EHA executive offices:

Didi Jasmin

Telephone + 33 (0) 1 57 27 68 37 didi.jasmin@univ-paris-diderot.fr

Ineke van der Beek

Telephone +31 (0) 70 345 55 63 i.vanderbeek@ehaweb.org

ESH-EHA SCIENTIFIC WORKSHOP

Innovative Therapies for Red Cell and Iron related Disorders

April 15-18, 2010

Cascais, Portugal

Program

Thursday, April 15t h 2010

20h00-21h00: KEYNOTE LECTURE I

The therapeutic potential of iPS cells

Friday, April 16th 2010 speaker pending

8h30-10h30: SESSION I: HEMATOPOIETIC STEM CELL (HSC) THERAPIES

Chair: E. Gluckman (Paris)

Allogeneic BMT in Sickle cell anemia

New Trends in HSC therapies

Panel Discussion

BMT versus CB-HSC in hemoglobinopathies

F. Bernaudin (Creteil)

E. Gluckman (Paris)

F. Locatelli (Pavia)

Selected oral presentations (15 min each)

10h30-11h00: Coffee break

11h00-13h00: SESSION II: FROM HSC TO ERYTHROCYTE

Chair: F. Grosveld (Rotterdam)

Expansion of HSCs

The molecular switching in erythroid differentiation

Programming the hemoglobin genes for therapies

Overcoming insertional adverse events of integrating gene vectors

13h00-15h00: Lunch

K. Humphries (Vancouver)

S. Orkin (Boston)

F. Grosveld (Rotterdam)

C. Baum (Hannover)

15h00-17h30: SESSION III: GENE THERAPY

Chair: P. Leboulch (Fontenay/Boston)

Selected oral presentations (15 min each)

Gene therapy of hemoglobin disorders

Design of lentiviral Vectors

Selected oral presentations (15 min each)

17h30-18h00: Coffee break

18h00-19h00: POSTER SESSION I: BIOTHERAPIES

P. Leboulch (Fontenay/Boston)

F-L. Cosset (Lyon)

Saturday, April 17th 2010

8h30-10h30: SESSION IV: IRON REGULATORY PATHWAY FOR THERAPIES

Chairs: C. Camaschella (Milano)

Heme and Iron recycling

Role of Hemojuvelin in iron deficiency and overload

The essential role of BMP6 in hepcidin regulation

C. Beaumont (Paris)

C. Camaschella (Milano)

M.P. Roth (Toulouse)

Selected oral presentations (15 min each)

10h30-11h00: Coffee break

11h00-13h00: SESSION V: THE HEPCIDIN EFFECTOR PATHWAY FOR THERAPIES

Chair: C. Beaumont (Paris)

Hepcidin agonists and antagonists

Targeting the hepcidin binding site of ferroportin

Relocating misdistributed iron by chelators

Selected oral presentations (15 min each)

13h00-15h00: Lunch

E. Nemeth (Los Angeles)

I. De Domenico (Salt Lake City)

I. Cabantchick (Jerusalem)

15h00-17h30: SESSION VI: INNOVATIVE THERAPIES FOR RED CELL DISORDERS (I)

Chair: M. Narla (New-York)

Erythrocyte acting therapies Y. Beuzard (Fontenay)

Gene active therapies

EPO therapy in hemoglobin disorders

Selected oral presentations (15 min each)

S.L. Thein (London)

F. Galacteros (Creteil)

17h30-18h00: Coffee break

18h00-19h00: POSTER SESSION II: IRON AND ERYTHROCYTE TARGETING THERAPIES

Sunday, April 18 th 2010

9h00-10h00: SESSION VII: INNOVATIVE THERAPIES FOR RED CELL DISORDERS (II)

Chair: F. Galacteros (Creteil)

Vascular acting therapies in Sickle cell disease

Heme oxygenase protects against red cell disorders

10h00-10h30: Coffee break

10h30-11h30: KEYNOTE LECTURE II

Erythrocyte targeting for therapies in malaria

End of the meeting

P-L. Tharaux (Paris)

M. Soares (Lisbon)

M. Narla (New-York)

Download